Fig. 7
From: Docetaxel-loaded pH/ROS dual-responsive nanoparticles for the targeted treatment of gastric cancer
In vivo antitumor efficacy of DTX, DTX/CA-Oxi-αCD NPs, and DTX/FA-CA-Oxi-αCD NPs in BGC-823 tumor-bearing mice. A Administration time after tumor inoculation. The mice received 2 mg/kg DTX or 2 mg/kg DTX nanoformulations every four days. B Images of excised tumors treated with free DTX or different nanoformulations (a) and representative T2 MR images of tumors (b). C Tumor growth curve after intravenous injection of DTX or different nanoformulations, n = 4. D Immunohistochemistry assay for ki67 and TUNEL detection in tumor tissues; scale bar represents 100 μm. E Semiquantitative analysis of ki67 expression (a) and TUNEL-positive areas in tumor tissues (b). *, significantly different at p < 0.05; **, significantly different at p < 0.01; ***, significantly different at p < 0.001; ****, significantly different at p < 0.0001